Ipca Laboratories reported a steady performance for the quarter ended December 31, 2025, with profit growth outpacing revenue expansion on a year-on-year (YoY) basis. The pharmaceutical major delivered improved operational efficiency despite moderate topline growth.
Revenue from operations for Q3 FY26 stood at ₹2,392.50 crore compared to ₹2,245.37 crore in the corresponding quarter last year, registering a growth of 6.55% YoY. Total income increased to ₹2,412.69 crore from ₹2,265.48 crore, reflecting a 6.50% YoY rise.
On the cost front, total expenses rose to ₹1,984.36 crore versus ₹1,897.56 crore in Q3 FY25, marking an increase of 4.57% YoY. The relatively lower growth in expenses compared to revenue supported operating profitability during the quarter.
Profit before exceptional items and tax climbed to ₹428.33 crore from ₹367.92 crore in the year-ago period, reflecting a strong 16.42% YoY growth. Including exceptional items, profit before tax came in at ₹445.98 crore as against ₹367.92 crore last year, translating into a 21.22% YoY increase.
At the bottom line level, profit attributable to owners of the company surged to ₹326.27 crore compared to ₹248.14 crore in Q3 FY25, recording a robust 31.49% YoY growth. The sharp rise in net profit indicates improved margins and operational leverage during the quarter.
